JP2003026589A - Medicine for preventing eye disease and improving visual sense - Google Patents

Medicine for preventing eye disease and improving visual sense

Info

Publication number
JP2003026589A
JP2003026589A JP2001249641A JP2001249641A JP2003026589A JP 2003026589 A JP2003026589 A JP 2003026589A JP 2001249641 A JP2001249641 A JP 2001249641A JP 2001249641 A JP2001249641 A JP 2001249641A JP 2003026589 A JP2003026589 A JP 2003026589A
Authority
JP
Japan
Prior art keywords
improving
extract powder
cassis
medicine
lutein ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001249641A
Other languages
Japanese (ja)
Inventor
Noboru Abe
昇 安部
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATURALLY PLUS KK
Original Assignee
NATURALLY PLUS KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATURALLY PLUS KK filed Critical NATURALLY PLUS KK
Priority to JP2001249641A priority Critical patent/JP2003026589A/en
Publication of JP2003026589A publication Critical patent/JP2003026589A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a medicine for preventing eye diseases and improving visual senses, capable of enhancing effects for preventing the eye diseases and improving the visual senses of a person overusing the eyes in VDT works accompanied by the popularization of TV games and OA equipments. SOLUTION: This medicine for preventing the eye diseases and improving the visual senses is characterized by using cassis extract powder having a visual sense-improving effect and a marigold extract (lutein ester) extremely useful for maintaining a healthy eyesight in the form of soft capsules. Thereby, the eyesight-improving effects, such as reflection deterioration-inhibiting action or a dark adaptation-inhibiting action, of the cassis extract powder can be increased and continued.

Description

【発明の詳細な説明】 【0001】 【発明の属する技術分野】この発明はカシスエキスパウ
ダーとルテインエステルをソフトカプセルにして摂取す
る事により、TVゲームやOA機器の普及に伴うVDT
作業(Visual Display Termina
l w0rk)で目を酷使する人の眼の病気の予防や視
覚改善の効果を高める眼病予防および視覚改善剤に関す
る事である。 【0002】 【従来の技術】近年TVゲームやOA機器の普及に伴う
VDT作業の増加によりますます目を酷使し、知らず知
らずのうちに目に大きな負担を掛けている。この様なブ
ラウン管等のモニタの凝視は眼精疲労だけでなく、肩こ
り、腰の疲れ、冷えなどの抹消血流不全を生じて、これ
を緩和するための医薬品または健康食品が強く求められ
ている。この社会的ニーズの高まりに対して、第二次大
戦中の英国空軍パイロットがアントシアニンを含むビル
ベリージャムを摂取して暗視力を得たと言う事から研究
が進められ、ビルベリージャムには網膜機能の改善作用
のある事が分かった。現在では、ビルベリーおよび同属
の栽培種であるブルーベリーが目の健康食品として使用
されている。しかし、これらの健康食品は眼精疲労にの
みに注目していて、パソコン、TVゲームなどのブラウ
ン管等から目に入る強い光に対しては注意が払われてい
なかった。 【0003】 【発明が解決しようとする課題】TVゲームやOA機器
の普及に伴うVDT作業の増加により目を酷使し、知ら
ず知らずのうちに目に大きな負担を掛けているので、ブ
ラウン管等のモニタの凝視によって生ずる眼精疲労を緩
和する補助食品とブラウン管等のモニタから目に入る強
い光に対して目を保護する補助食品の組み合わせによっ
て眼病予防および視覚改善剤の効果を上げる事が出来な
いか研究した。 【0004】 【課題を解決するための手段】a)カシスエキスパウダ
ー カシスは6月から8月に濃紫色で酸味のある小さい果実
をつけるベリー類の一種で、ヨーロッパからアジアにか
けて業寒冷地に広く成育するユキノシタ科の小灌木であ
る。果実の中にはビタミンCやミネラル類が豊富なこと
と、アントシアニン含量が高いことが知られている。カ
シスには主として4種類のアントシアニンが含まれてい
るが、その中の約60%が抗酸化力が優れているデルフ
ィニジン配糖体である。カシスエキスパウダーはカシス
冷凍果実をペクチナーゼ処理後、圧搾・濾過し、膜処理
により濃縮し、スプレードライにより粉末化するとアン
トシアニン濃度7%以上、水分5%以下を含有する粉末
になる。本実験で使用したカシスエキスパウダーの分析
値は水分2.3%、アントシアニン9.1%である。こ
の抗酸化性を持つカシスエキスパウダーはVDT作業に
伴う仮性近視の抑制効果、眼精疲労の抑制、近視化進行
の抑制の効果が認められ視覚改善剤として用いられてい
る。カシスエキスパウダーは視覚改善に留まらず、肩凝
り、腰の疲れ、冷えなどの抹消血流不全に起因する諸症
状の緩和にも効果がある。 b)ルテインエステル ルテインエステルはリンゴ、オレンジ、パパイヤ、モ
モ、ミカン、カボチャなどの果物や野菜に多く含まれて
いるカロチノイドの一つである。主栄養素としては認め
られていないがビタミンに似た働きをしていて、健全な
視力を保つためには極めて有用であることは認められて
いる。本実験で使用するルテインエステルはマリーゴー
ルドフラワーから抽出された結晶ルテインエステルの懸
濁液からなり、健康食品及び一般食品用素材として用い
られている。人の消化管の中では徐々にルテインに分解
されて血液中に吸収され体の組織に運ばれるので持続性
をもたらす事が出来る。光は視覚には不可欠であるが、
パソコン、TVゲームなどのブラウン管らのモニタから
でる強い光は、特に目に有害なフリーラジカルを生む化
学反応を起こす。そこで、人間の目の中には正常な視力
を維持するためにルテインともう一つのカロチノイドで
あるゼアキサンチンの層が目の中心部の黄班中に存在
し、フリーラジカルを生産する青色光を吸収、濾過して
取り除き網膜を保護している。従って、黄班色素のルテ
インとゼアキサンチンは網膜全体に必要かつ重要な色素
である。しかし、黄班色素の密度はライフスタイルや食
事にも強く影響され、喫煙者は非喫煙者に比べて黄班色
素が稀薄である。又、ケール、ホウレンソウ、ブロッコ
リというルテインの多く含む食品を食べている人は黄班
色素が厚く、正常視力を持つことが出来る。本発明者は
視覚改善効果のあるカシスエキスパウダーと健全な視力
を保つためには極めて有用なマリーゴールド抽出物(ル
テインエステル)を合わせてソフトカプセルにして用い
る事により、カシスエキスパウダーの屈折低下抑制作
用、暗順応抑制作用等の視覚改善効果が増強持続するこ
とを見出だしたのである。 【0005】カシスエキスパウダーとマリーゴールド抽
出物(ルテインエステル)をソフトカプセルにする事に
より、薬効成分を徐々に溶出させて持続性を持たせ、マ
リーゴールド抽出物の中のルテインエステルは消化管の
中では徐々にエステルがはずれルテインになり、血液中
に吸収されて体の組織に運ばれるので持続性をもたらす
ことが出来る。これ等の事が眼病予防および視覚改善の
効果をより大きくしていると思われるが、本発明の効果
については現在研究中である。今まで視覚改善と言う
と、仮性近視の抑制効果、眼精疲労の抑制、近視化進行
の抑制にのみ注目して、パソコン、TVゲームなどのブ
ラウン管等のモニタの強い光が目に入る事に余り注目し
ていなかった。目に悪い夏の紫外線をカットするためサ
ングラスを掛ける様に、本発明は人の目の中にある黄班
色素の密度を高めてパソコン、TVゲームなどのブラウ
ン管等のモニタから出る強い光をカットして、仮性近視
の抑制、眼精疲労の抑制、近視化進行の抑制をしようと
するものである。 【0006】実験1 被験者12人がマリーゴールド抽出物(ルテインエステ
ル)を毎日30mgずつ140日間摂取すると、20日
後に被験者全員の目の黄班色素が増加し始めた。黄班密
度の平均増加率は39%および21%の範囲で、これに
よって光受容体に達する青色光がおよそ30%から40
%減少した。「実験1」の結果から分かるように、マリ
ーゴールド抽出物(ルテインエステル)は摂取してもす
ぐに黄班色素が増加すると言う効果が出ないので、ある
一定の期間を摂取した後にカシスエキスパウダーの実験
データーを取る必要がある。 【0007】 【発明の実施の形態】製造方法については実施例1、実
施例2に示す。 【0008】実施例1 マリーゴールド抽出物(ルテインエステル)90g,カ
シスエキスパウダー90g,VB1.5g,VB
1.5gビタミンE150gを良く混合してから、通
常の方法でソフトカプセル3000個を製造する。 実施例2 カシスエキスパウダー150g,VB1.5g,VB
1.5gビタミンE150gを良く混合してから、通
常の方法でソフトカプセル3000個を製造する。 【0009】実験2 実施例1で製造したソフトカプセルと実施例2で製造し
たソフトカプセルを用いて屈折低下抑制作用、暗順応抑
制作用について調べた。 a)屈折低下抑制作用 20名の健常人を用いて2時間のパソコン作業をして誘
起される仮性近視の抑制効果を実施例2で製造したカシ
スエキスパウダーのソフトカプセルと実施例1で製造し
たマリーゴールド抽出物(ルテインエステル)とカシス
エキスパウダーの混合されたソフトカプセルで比較し
た。実施例2のカシスエキスパウダー50mgを含有す
るソフトカプセルを摂取した組では近視化は見られなか
った。一方、実施例1のマリーゴールド抽出物(ルテイ
ンエステル)とカシスエキスパウダーの混合されたソフ
トカプセルを摂取する組は予め20日前よりマリーゴー
ルド抽出物(ルテインエステル)を毎日30mgずつ摂
取させた後、実施例1で製造したカシスエキスパウダー
30mgとマリーゴールド抽出物30mg含有するソフ
トカプセルを摂取した組でも近視化は見られなかった。
即ち、マリーゴールド抽出物(ルテインエステル)とカ
シスエキスパウダーを併用して用いるとカシスエキスパ
ウダーの量が通常の60%で同じ仮性近視の抑制効果を
出すことが分かった。 b)暗順応抑制作用 12名の健常人を用いて両眼の暗順応閾値を測定した。
プラセボと実施例2のカシスエキスパウダー50mgを
含有するソフトカプセルを摂取した組ではプラセボとの
間に暗順応の低下との有意差がみられた。一方、実施例
1で製造したソフトカプセルを摂取する組は予め20日
前よりマリーゴールド抽出物(ルテインエステル)を毎
日30mgずつ摂取させた後、実施例1で製造したカシ
スエキスパウダー30mgとマリーゴールド抽出物(ル
テインエステル)30mg含有するソフトカプセルを摂
取した組とカシスエキスパウダー50mgを摂取した組
との間に暗順応の低下の有意差がみられ無かった。従っ
てが、マリーゴールド抽出物(ルテインエステル)とカ
シスエキスパウダーの混合物を用いるとカシスエキスパ
ウダーの量が通常の60%で同じ暗順応抑制作用の効果
を出すことが分かった。 【0010】 【発明の効果】今まで視覚改善と言うと、仮性近視の抑
制効果、眼精疲労の抑制、近視化進行の抑制にのみ注目
して、パソコン、TVゲームなどのブラウン管のモニタ
の強い光が目に入る事に余り注目していなかった。そこ
で、目に悪い夏の紫外線をカットするためサングラスを
掛ける様に、人の目の中にある黄班色素の密度を高めて
光をカットして、仮性近視の抑制、眼精疲労の抑制、近
視化進行の抑制をさせるものである。本発明者は視覚改
善効果のあるカシスエキスパウダーと健全な視力を保つ
ためには極めて有用なマリーゴールド抽出物(ルテイン
エステル)を合わせてソフトカプセルにして用いる事に
より、カシスエキスパウダーの屈折低下抑制作用、暗順
応抑制作用等の視覚改善効果を従来の摂取量の60%で
済ませ、しかも持続さる事が出来たのである。この理由
は、カシスエキスパウダーとマリーゴールド抽出物(ル
テインエステル)をソフトカプセルにする事により、薬
効成分を徐々に溶出させた事とマリーゴールド抽出物
(ルテインエステル)が消化管の中で徐々にエステルが
はずれルテインになり、血液中に吸収されて体の組織に
運ばれるので持続性をもたらすことが出来、眼病予防お
よび視覚改善の効果をより大きくしていると思われる
が、効果を増大させるメカニズムについては現在研究中
である。 【0011】「実験2」の結果から明らかなように、マ
リーゴールド抽出物(ルテインエステル)とカシスエキ
スパウダーを混合したソフトカプセルを摂取すると、カ
シスエキスパウダーを単独で用いた時より屈折低下抑制
作用、暗順応抑制作用が増強され、カシスエキスパウダ
ーを単独で用いた時の量の60%で同等の効果を出す事
ができる。しかし、この時、マリーゴールド抽出物(ル
テインエステル)を予め前から摂取して置く必要がある
が、本発明のソフトカプセルにはマリーゴールド抽出物
(ルテインエステル)が入っているので長期間摂取して
いれば効果は同様に出ることは明らかである。また、マ
リーゴールド抽出物(ルテインエステル)を長期間摂取
する事により、目の中にある黄班色素の密度が高まり有
害な光をカットするので、TVゲームやOA機器の普及
に伴うVDT作業で目を酷使する人の眼の病気の予防に
もつながるのである。
Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a VDT accompanying the spread of TV games and OA equipment by ingesting cassis extract powder and lutein ester in a soft capsule.
Work (Visual Display Termina)
The present invention relates to an agent for preventing eye diseases and improving vision, which enhances the effects of preventing eye diseases and improving vision of people who overuse their eyes at 1 w0rk). 2. Description of the Related Art In recent years, with the increase in VDT work accompanying the spread of TV games and OA equipment, eyes are increasingly overworked, and a heavy burden is imposed on the eyes without knowing it. The gaze of such a monitor such as a cathode ray tube causes not only eye strain but also peripheral blood flow insufficiency such as stiff shoulders, waist fatigue and coldness, and there is a strong demand for pharmaceuticals or health foods to alleviate this. . In response to this growing social need, research has been promoted because the Royal Air Force pilot during World War II gained night vision by ingesting bilberry jam containing anthocyanins, and bilberry jam improved retinal function. It turned out to be working. At present, bilberries and their cultivars, blueberries, are used as eye health foods. However, these health foods focus only on eye strain and do not pay attention to strong light entering the eyes from cathode ray tubes such as personal computers and TV games. [0003] The increase in VDT work accompanying the spread of TV games and OA equipment overworked the eyes and put a heavy burden on the eyes without knowing it. The combination of supplements to alleviate eye strain caused by staring eyes and supplements to protect the eyes against intense light entering the eyes from monitors such as cathode ray tubes improve the effects of eye disease prevention and vision improvers? Studied. Means for Solving the Problems a) Cassis extract powder Cassis is a kind of berries that give dark purple and sour small fruits from June to August, and are widely used in industrial cold regions from Europe to Asia. It is a small shrub of Saxifragaceae that grows. It is known that the fruits are rich in vitamin C and minerals and high in anthocyanin content. Cassis mainly contains four types of anthocyanins, of which about 60% are delphinidin glycosides having excellent antioxidant activity. Cassis extract powder is a powder containing an anthocyanin concentration of 7% or more and a water content of 5% or less when frozen fruits of cassis are treated with pectinase, squeezed and filtered, concentrated by membrane treatment, and powdered by spray drying. The analysis value of the cassis extract powder used in this experiment was 2.3% water and 9.1% anthocyanin. Cassis extract powder having this antioxidant property is used as a visual improving agent because it has an effect of suppressing pseudomyopia associated with VDT work, an effect of suppressing asthenopia, and an effect of suppressing progression of myopia. Cassis extract powder is effective not only for improving visual acuity, but also for alleviating various symptoms caused by peripheral blood flow insufficiency such as stiff shoulders, waist fatigue and coldness. b) Lutein ester Lutein ester is one of the carotenoids contained in fruits and vegetables such as apples, oranges, papayas, peaches, mandarins, and pumpkins. Although not recognized as a main nutrient, it acts like a vitamin and has been found to be extremely useful for maintaining healthy vision. The lutein ester used in this experiment consists of a suspension of crystalline lutein ester extracted from marigold flower, and is used as a material for health foods and general foods. In human digestive tract, it is gradually broken down into lutein, absorbed into the blood, and transported to the body's tissues. Light is essential for vision,
Intense light emitted from monitors of cathode ray tubes and the like in personal computers and TV games causes a chemical reaction that produces free radicals particularly harmful to the eyes. So, in order to maintain normal vision in the human eye, a layer of lutein and another carotenoid, zeaxanthin, is present in the central macula of the eye and absorbs blue light that produces free radicals It is filtered off to protect the retina. Thus, the macula pigments lutein and zeaxanthin are necessary and important pigments throughout the retina. However, the density of the macula pigment is strongly influenced by lifestyle and diet, and smokers have less macula pigment than non-smokers. Also, those who eat foods containing a lot of lutein such as kale, spinach and broccoli have thick macula pigment and can have normal vision. The present inventor uses a cassis extract powder having an effect of improving vision and a marigold extract (lutein ester), which is extremely useful for maintaining healthy vision, in a soft capsule form, and uses the same in a soft capsule to suppress the refraction of cassis extract powder. It was found that the visual improvement effects such as the dark adaptation suppression effect were continuously enhanced. [0005] By making cassis extract powder and marigold extract (lutein ester) into a soft capsule, the medicinal ingredient is gradually eluted to have a long lasting effect, and the lutein ester in the marigold extract is contained in the digestive tract. Then, the ester gradually comes off and becomes lutein, which is absorbed into the blood and transported to the body tissues, thus providing sustainability. These facts seem to enhance the effects of preventing eye diseases and improving vision, but the effects of the present invention are currently being studied. Until now, visual improvement has been focused only on the effect of suppressing pseudomyopia, the suppression of eye strain, and the suppression of progression of myopia, and the intense light of monitors such as cathode-ray tubes for personal computers and TV games enters the eyes. I didn't pay much attention. The present invention increases the density of the macula pigment in the human eye and cuts the strong light emitted from monitors such as cathode ray tubes for personal computers and TV games, like wearing sunglasses to cut off bad summer ultraviolet rays. Then, it is intended to suppress pseudomyopia, suppress asthenopia, and suppress myopia progression. Experiment 1 When twelve subjects ingested marigold extract (lutein ester) at a dose of 30 mg daily for 140 days, the macular pigment of all eyes began to increase after 20 days. Average increases in macula density ranged from 39% and 21%, whereby blue light reaching the photoreceptor was approximately 30% to 40%.
%Diminished. As can be seen from the results of “Experiment 1”, marigold extract (lutein ester) does not have the effect of increasing the macula pigment immediately after ingestion, so after taking a certain period of time, cassis extract powder It is necessary to take experimental data. Embodiments 1 and 2 show a manufacturing method. Example 1 90 g of marigold extract (lutein ester), 90 g of cassis extract powder, 1.5 g of VB 1 , VB
2 1.5 g Vitamin E 150 g is mixed well, and then 3000 soft capsules are manufactured by a usual method. Example 2 cassis extract powder 150g, VB 1 1.5g, VB
2 1.5 g Vitamin E 150 g is mixed well, and then 3000 soft capsules are manufactured by a usual method. Experiment 2 Using the soft capsule manufactured in Example 1 and the soft capsule manufactured in Example 2, the effect of suppressing refraction reduction and the effect of suppressing dark adaptation were examined. a) Inhibition of Refraction Reduction The effect of suppressing pseudomyopia induced by working with a personal computer for 20 hours using 20 healthy persons was confirmed by the soft capsule of cassis extract powder produced in Example 2 and Mary produced in Example 1. Comparison was made with soft capsules in which gold extract (lutein ester) and cassis extract powder were mixed. No myopia was observed in the group that ingested the soft capsule containing 50 mg of the cassis extract powder of Example 2. On the other hand, in the group in which the soft capsule in which the marigold extract (lutein ester) and the cassis extract powder were mixed in Example 1 was taken, 30 mg of the marigold extract (lutein ester) was ingested daily for 20 days beforehand, and then No myopia was observed in the group in which the soft capsule containing 30 mg of the cassis extract powder produced in Example 1 and 30 mg of the marigold extract was ingested.
That is, it was found that when the marigold extract (lutein ester) and the cassis extract powder were used in combination, the same effect of suppressing pseudomyopia was obtained when the amount of the cassis extract powder was 60% of the normal amount. b) Dark adaptation inhibitory action Dark adaptation thresholds of both eyes were measured using 12 healthy persons.
In the group that took the placebo and the soft capsule containing 50 mg of the cassis extract powder of Example 2, a significant difference was observed between the placebo and the placebo, in which the dark adaptation was reduced. On the other hand, the group ingesting the soft capsules produced in Example 1 was ingested 30 mg of marigold extract (lutein ester) daily for 20 days beforehand, and then 30 mg of the cassis extract powder produced in Example 1 and marigold extract. (Lutein ester) There was no significant difference in the reduction of dark adaptation between the group ingesting the soft capsule containing 30 mg and the group ingesting the cassis extract powder 50 mg. However, it was found that when a mixture of marigold extract (lutein ester) and cassis extract powder was used, the same effect of dark adaptation was exerted when the amount of cassis extract powder was 60% of the normal amount. According to the present invention, visual improvement has been described only by focusing on suppression of pseudomyopia, suppression of eye strain, and suppression of progression of myopia. He didn't pay much attention to seeing the light. Therefore, like wearing sunglasses to cut off the summer ultraviolet rays that are bad for the eyes, the density of the macula pigment in the human eye is increased and the light is cut to suppress pseudomyopia, suppression of eye strain, It is intended to suppress the progress of myopia. The present inventor uses a cassis extract powder having an effect of improving vision and a marigold extract (lutein ester), which is extremely useful for maintaining healthy vision, in the form of a soft capsule, which is used to suppress the refraction of cassis extract powder. In addition, the visual improvement effects such as the effect of suppressing dark adaptation were completed at 60% of the conventional intake, and could be maintained. The reason is that the cassis extract powder and marigold extract (lutein ester) are made into soft capsules, so that the medicinal ingredient is gradually eluted and the marigold extract (lutein ester) is gradually esterified in the digestive tract. It becomes lutein, and it is absorbed into the blood and transported to the body tissue, which can provide persistence, which seems to be more effective in preventing ocular diseases and improving vision, but a mechanism that increases the effect Is currently under study. As is apparent from the results of "Experiment 2", when soft capsules in which marigold extract (lutein ester) and cassis extract powder were mixed were taken, the effect of suppressing the decrease in refractive index was lower than when cassis extract powder was used alone. The effect of suppressing dark adaptation is enhanced, and the same effect can be obtained at 60% of the amount when cassis extract powder is used alone. However, at this time, it is necessary to take marigold extract (lutein ester) beforehand, but since the soft capsule of the present invention contains marigold extract (lutein ester), it has been taken for a long time. It is clear that the effect will be the same. In addition, long-term ingestion of marigold extract (lutein ester) increases the density of the macula pigment in the eyes and cuts off harmful light. It also helps prevent eye diseases for those who overuse the eyes.

Claims (1)

【特許請求の範囲】 【請求項1】 カシスエキスパウダーとルテインエステ
ルをソフトカプセルにして用いる事を特徴とする眼病予
防および視覚改善剤。
[Claim 1] An agent for preventing ocular diseases and improving vision, wherein cassis extract powder and lutein ester are used as soft capsules.
JP2001249641A 2001-07-16 2001-07-16 Medicine for preventing eye disease and improving visual sense Pending JP2003026589A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001249641A JP2003026589A (en) 2001-07-16 2001-07-16 Medicine for preventing eye disease and improving visual sense

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001249641A JP2003026589A (en) 2001-07-16 2001-07-16 Medicine for preventing eye disease and improving visual sense

Publications (1)

Publication Number Publication Date
JP2003026589A true JP2003026589A (en) 2003-01-29

Family

ID=19078610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001249641A Pending JP2003026589A (en) 2001-07-16 2001-07-16 Medicine for preventing eye disease and improving visual sense

Country Status (1)

Country Link
JP (1) JP2003026589A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005065525A (en) * 2003-08-20 2005-03-17 Koyo Shokai:Kk Lutein- and blueberry-containing drink
WO2005097151A1 (en) * 2004-04-06 2005-10-20 Four Leaf Japan Co., Ltd. Antioxidant composition and products containing the same
JP2008110933A (en) * 2006-10-30 2008-05-15 Four Leaf Japan:Kk Antioxidant composition and product containing the same
JP2008271878A (en) * 2007-04-27 2008-11-13 Wakasa Seikatsu:Kk Novel food and drink
JP2009513641A (en) * 2005-10-26 2009-04-02 アボット・ラボラトリーズ Infant formulations containing docosahexaenoic acid and lutein
US8263147B2 (en) 2005-10-26 2012-09-11 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
JP2015065927A (en) * 2013-09-30 2015-04-13 キリン株式会社 Manufacturing method of composition containing polysaccharide derived from cassis fruit
CN105077260A (en) * 2015-09-22 2015-11-25 哈尔滨宝德生物技术股份有限公司 Xylitol and lutein granule capable of relieving eyestrain and preparation method of xylitol and lutein granule
CN106072584A (en) * 2016-07-13 2016-11-09 大兴安岭超越野生浆果开发有限责任公司 A kind of lutein ester and the compound edible health care product of Oleum Hippophae
CN114939142A (en) * 2022-05-10 2022-08-26 仙乐健康科技股份有限公司 Composition for resisting blue light
EP3513795B1 (en) * 2016-09-13 2023-07-19 Megumi Tanaka Visual function improvement agent, and method for improving visual function

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005065525A (en) * 2003-08-20 2005-03-17 Koyo Shokai:Kk Lutein- and blueberry-containing drink
WO2005097151A1 (en) * 2004-04-06 2005-10-20 Four Leaf Japan Co., Ltd. Antioxidant composition and products containing the same
US9861120B2 (en) 2005-10-26 2018-01-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
JP2009513641A (en) * 2005-10-26 2009-04-02 アボット・ラボラトリーズ Infant formulations containing docosahexaenoic acid and lutein
JP2012131802A (en) * 2005-10-26 2012-07-12 Abbott Lab Infant preparation containing docosahexaenoic acid (dha) and lutein
US8263147B2 (en) 2005-10-26 2012-09-11 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
US10342244B2 (en) 2005-10-26 2019-07-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
JP2008110933A (en) * 2006-10-30 2008-05-15 Four Leaf Japan:Kk Antioxidant composition and product containing the same
JP2008271878A (en) * 2007-04-27 2008-11-13 Wakasa Seikatsu:Kk Novel food and drink
JP2015065927A (en) * 2013-09-30 2015-04-13 キリン株式会社 Manufacturing method of composition containing polysaccharide derived from cassis fruit
CN105077260A (en) * 2015-09-22 2015-11-25 哈尔滨宝德生物技术股份有限公司 Xylitol and lutein granule capable of relieving eyestrain and preparation method of xylitol and lutein granule
CN106072584A (en) * 2016-07-13 2016-11-09 大兴安岭超越野生浆果开发有限责任公司 A kind of lutein ester and the compound edible health care product of Oleum Hippophae
EP3513795B1 (en) * 2016-09-13 2023-07-19 Megumi Tanaka Visual function improvement agent, and method for improving visual function
CN114939142A (en) * 2022-05-10 2022-08-26 仙乐健康科技股份有限公司 Composition for resisting blue light

Similar Documents

Publication Publication Date Title
Mozaffarieh et al. The role of the carotenoids, lutein and zeaxanthin, in protecting against age-related macular degeneration: a review based on controversial evidence
Sperduto et al. Do we have a nutritional treatment for age-related cataract or macular degeneration?
CN106333885A (en) Plant extract and eye essence liquid
WO2005110375A1 (en) Nutritional supplement for treatment of ocular diseases
CN104147081A (en) Blueberry lutein soft capsule for improving eyesight and manufacturing method thereof
CN103566049A (en) Composition for improving density of macular pigment in eyes and preventing or treating age-related macular degeneration
MX2008004981A (en) Compositions for treatment of eye diseases.
JP2003026589A (en) Medicine for preventing eye disease and improving visual sense
JP2008271878A (en) Novel food and drink
CN101890116A (en) Anthocyanin health-care eye drops and preparation method thereof
JP2005065525A (en) Lutein- and blueberry-containing drink
CN101019914A (en) Soft capsule containing lutein and its prepn
JP2003238442A (en) Composition for eyes health
JP2002017295A (en) Health auxiliary food product having activity for ameliorating eye disease and activity for keeping function of eye
CN106692187A (en) Composition for improving visuognosis persistence and protecting eye health
CN109010790A (en) A kind of composition and its application for improving eye strain
CN105520137A (en) Healthy food with functions of relieving asthenopia and protecting eyesight
CN101612161A (en) A kind of eye medicine combination and preparation thereof
CN109731027A (en) Facilitate the composition and preparation method thereof of alleviation visual fatigue and xerophthalmia series symptom
CN110559314A (en) Composition for protecting eyesight
Sawant Unique Australian Native Botanical-Lemon Myrtle as a Natural Source of Ocular Health Super-Nutrient
Saving Age Related Macular Degeneration
US20190125694A1 (en) Method for treatment of visual stress conditions and compositions used therein
CN109875048A (en) Eyeshield composition and its application
AU2020352751B2 (en) Composition of a dietary supplement and/or a nutritional additive for food, a unitary dosage form of said composition, and their use for improvement of the quality of visual performance including contrast sensitivity in persons in need of such an improvement, including persons suffering from at least one eye disease, particularly vitreous floaters